Porvair plc (PRV) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

67OpportunityDD: Jun 21, 2026Analyst: 80

paidPrice at analysis date

810.0 (21/06/2026)

domainMkt cap

£377M

pie_chartShares

46.5M

candlestick_chart52W

660-920

trending_downShort interest

INFOLSE Main MarketIndustrials825 employeesFounded 1985

Verdict: Favorable Risk/Reward — Asymmetric Special Situation

Quality UK specialist filtration compounder (aerospace, lab, metals) with net-cash balance sheet trading at ~10.5x EV/EBITDA fwd, ~30% discount to UK quality industrials median. Activist Richard Bernstein publicly pushing chairman for strategic alternatives (May 19, 2026); 24% AGM no-confidence vote on chairman creates real catalyst path. Floor anchored by stable cash-generative business; upside from re-rating to peer multiple and/or PE/strategic takeout premium.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-06-21

Porvair plc (PRV.L)

Specialist filtration · LSE Main · King's Lynn, UK

"Quality compounder at discount — activist optionality on top of solid intrinsic case"

Net cash B/S 22Y dividend record Multi-BU defensive mix Activist optionality Board governance flag

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Gov./ESG

/2 pts

💡 Fair Value Estimate — Sum-of-the-Parts EV/EBITDA + DCF cross-check

Fair value base case

960.0

Range: 720.0-1250.0

Price at analysis date: 810.0 (21/06/2026)

Base upside/downside: +19%

Methodology: Primary SotP-EV/EBITDA on FY26E (blended implied multiple 12.5x, within 15% of nominal 13.5x peer median). DCF cross-check (WACC 8.0%, terminal 2.5%) ≈ 950p, converges within 3%. Probability-weighted FV = 25%×1,250 + 50%×960 + 25%×730 = 975p ≈ 980p, matching analyst consensus mid-point. Sensitivity: +/-2x on blended multiple moves base FV +/-160p (~17%). Asymmetry ratio (Bull/|Bear%|): 54%/10% = 5.4x — passes 2.5x screening gate. ⚠ Not investment advice.

Component	Assumption	$/share
Aerospace & Industrial EV	FY26E EBITDA £15M (18% margin on £85M rev) × 13x (aerospace specialist adj.) = £195M / 46.5M	+419
Laboratory EV	FY26E EBITDA £14M (21% margin on £68M rev) × 15x (lab consumable defensive) = £210M / 46.5M	+452
Metal Melt Quality EV	FY26E EBITDA £6M (14% margin on £43M rev) × 8x (cyclical industrial) = £48M / 46.5M	+103
Net cash position	(£22.87M cash - £14.43M debt) = £8.44M / 46.5M shares	+18
Central costs & pension	Capitalized HQ overhead drag -£15M (3x £5M annual) / 46.5M	-32
SotP fair value (base)	Sum of rows above; total equity ≈ £447M	≈ 960p

Bull

1,200–1,300p

Probability: 25%

Strategic review delivers takeover at 35-45% premium to intrinsic value. PE infrastructure fund or strategic (Pall, Donaldson, Filtronic, Mott Corporation) bids for high-margin Lab + A&I assets. Bernstein campaign succeeds in forcing process.

Base

816.0-1104.0

Probability: 50%

Standalone re-rating to ~13x EV/EBITDA fw as H1 26 confirms aerospace ramp, lab destock fades. Activist pressure forces board renewal but no full sale. Capital allocation discipline improves.

Bear

680–780p

Probability: 25%

Aerospace cycle softens, lab destock persists into FY27. Bernstein campaign dies on the vine, multiple compresses to 8.5-9x EV/EBITDA. Quality of business floors the downside near 52W low (660p).

Methodology: Methodology: Primary SotP-EV/EBITDA on FY26E (blended implied multiple 12.5x, within 15% of nominal 13.5x peer median). DCF cross-check (WACC 8.0%, terminal 2.5%) ≈ 950p, converges within 3%. Probability-weighted FV = 25%×1,250 + 50%×960 + 25%×730 = 975p ≈ 980p, matching analyst consensus mid-point. Sensitivity: +/-2x on blended multiple moves base FV +/-160p (~17%). Asymmetry ratio (Bull/|Bear%|): 54%/10% = 5.4x — passes 2.5x screening gate. ⚠ Not investment advice. Not investment advice.

warning

🚨 STALE PRICE WARNING

Working price 810p sourced from multiple analyst-target references published in early-mid June 2026 (Stockopedia, MarketBeat) but the exact close date for 2026-06-19 (target T-1 trading session) could not be cross-verified from real-time sources before report generation. Most recent fully-verified close: 860p on 2026-05-28 (T-17 trading days). Recent reference range: 660-920p (52-week). All upside/downside math anchored on 810p; verify intraday quote on broker before any position-sizing decision.

⚠ Methodology note: UK small-cap multi-BU industrial. Primary fair value method = Sum-of-the-Parts EV/EBITDA per business unit, cross-checked vs DCF. Activist scenario modeled as Bull case probability-weight (25%), NOT embedded as base case — report does not assume sale will happen.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟢 Short Interest

<1%

No material short position on AIM/Main Market disclosure thresholds (UK 0.5%). Free float low (~80%), little institutional shorting interest. Squeeze risk negligible.

🟢 Share dilution (1Y)

~0%

Share count stable at 46.5M YoY. No equity issuance since 2019. Modest LTIP dilution (<0.5%/yr) offset historically by small buybacks.

🟢 Buyback

Capacity

No active programme but AGM authority for up to 10% buyback exists. Net cash balance sheet + activist pressure makes buyback a credible capital return lever.

Short Interest — context

PRV.L — <1%

<1%

Clean cap structure: zero dilution, low SI, net-cash B/S. Activist Richard Bernstein holds a "small stake" in personal capacity (not via fund vehicle), so no 13D-equivalent UK disclosure required; situation closer to investor advocacy than formal proxy fight. AGM 2026: 24% no-vote against chairman John Nicholas's re-election is the hard data point on board dissatisfaction; insider buying in April 2026 (Hooman Javvi, £99k) signals internal alignment with sale thesis.

$Financial analysis — FY 2025 (Nov-end)

Revenue FY25

£194.0M

+0.7% YoY (cc +3%)

Net income FY25

£18.2M

+10.1% YoY

EBITDA TTM

£32.8M

16.9% margin

Net cash

£8.4M

Zero leverage

Item	FY23	FY24	FY25	FY26E	Guidance 2026
Revenue (£M)	187.2	192.6	194.0	~204	Mid-single-digit cc growth
EBITDA (£M)	30.8	30.5	32.8	~35	Margin expansion bias
Net income (£M)	16.5	16.5	18.2	~19.6	Implied via fwd P/E 19.2x
EPS (p)	35.5	35.5	39.0	~42	Consensus mid-Jun 2026
Net cash (£M)	6.2	7.1	8.4	~12	Strong cash conversion
DPS (p)	6.4	6.5	6.7	~7.0	22-year unbroken record

Note: FY ends 30 Nov. FY26E figures are model estimates derived from consensus EPS (~42p × 46.5M shares = £19.5M NI) + management H1 cc growth commentary; not official guidance. Cash flow conversion historically >100% of net income.

Half-year dynamics — last 5 halves (Porvair reports H1/H2)
Metric	H1 24	H2 24	H1 25	H2 25	H1 26E
Revenue (£M)	92.5	100.1	95.3	98.7	~100
Gross margin %	49.8%	50.2%	50.0%	50.4%	~50%
Adj. operating profit (£M)	10.2	11.8	10.3	12.0	~10.8
End-of-period cash (£M)	15.1	18.4	19.2	22.9	~24

Financial position and sustainability

Cash conversion (NI → FCF)

~95%

ROCE (post-tax)

~16%

Dividend cover (x)

5.8x

Leverage (Net debt/EBITDA)

-0.3x

account_tree

Business model — Specialist filtration, multi-end-market mix

Three-segment specialist industrial — aerospace + lab + metals

Porvair is a UK-listed specialist filtration and environmental technology group. The Aerospace & Industrial division supplies fluid and gas filtration to commercial aerospace OEMs (Boeing, Airbus tier-1 suppliers), defence and energy customers, with long-cycle qualification moats. The Laboratory division designs consumables (sample preparation, microplates) for biopharma, contract research and analytical labs — high gross margin, recurring consumable nature. Metal Melt Quality serves aluminium and steel foundries with ceramic filters and molten-metal sensors — the most cyclical segment, tied to auto and construction end-markets. Mix is structurally improving: Lab + A&I ≈ 78% of revenue at higher EBITDA margin vs MMQ.

Aerospace & Industrial ~£85M FY26E (43% rev) 🟢 ramping Filtration for jet engines (lube, hydraulic, fuel), gas turbines, energy. Long qualification cycles = competitive moat. Tailwind: aerospace build-rate recovery + defence spend. Target EBITDA margin 18-20%. Laboratory ~£68M FY26E (35% rev) 🟢 defensive Microplates, sample prep consumables for biopharma + analytical labs. Recurring consumable revenue. Biopharma capex destocking 2024-25 ending. Target EBITDA margin 20-22%. Metal Melt Quality ~£43M FY26E (22% rev) 🟡 cyclical Ceramic filters, molten-metal sensors for foundries (auto, construction). Most cyclical BU. Margins compress in down-cycle. Target EBITDA margin 12-15%.

Strategic value driver for activist case: A&I and Lab segments together (78% rev, >85% of EBITDA) have natural strategic acquirer interest (Pall/Cytiva, Donaldson, Mott Corporation, Filtronic, PE infrastructure funds). MMQ could be divested as standalone or spun. SotP analysis suggests sum of pure-play parts > current EV.

gavel

Legal, regulatory and risk analysis

Activist non-binding nature

High

Richard Bernstein holds stake "in personal capacity" with no fund vehicle deploying capital. No formal 13D-equivalent campaign, no slate of director nominees, no stated economic interest at this stage. Pressure could fizzle without execution.

Aerospace cycle exposure

Moderate

A&I segment (43% rev) tied to OEM build rates (Boeing 737 MAX, Airbus A320 family). Any production cut announcement at Airbus/Boeing flows through with 6-9 month lag. Mitigated by aftermarket revenue mix.

Lab end-market destock

Moderate

Biopharma + academic capex weak through 2024-25; consumable demand softening. Cycle bottom appears reached but FY26 inflection still to be confirmed by H1 26 interims (29 Jun 2026).

FX translation drag

Low

~60% revenue in USD/EUR. GBP strength reduces reported revenue; FY25 saw ~2.3% FX headwind. Operating margin partially natural-hedged via overseas production.

Low free float / liquidity

Moderate

£377M market cap, <£0.5M average daily turnover. Institutional inclusion limited. Position-building/exit takes weeks. Adverse fill risk on news-driven moves.

Board governance signal

Moderate

AGM 2026: 24% vote against chairman John Nicholas's re-election — well above 20% UK Code red-flag threshold. Forces formal response and consultation; raises chance of board renewal in 12 months.

Strategic acquirer interest

Positive

Filtration M&A active — Cytiva/Pall, Donaldson, Mott, Filtronic active consolidators. A&I + Lab standalone valuations from precedent deals (Solenis, Roper sub-deals) imply >current EV.

Net cash balance sheet floor

Positive

£8.4M net cash, zero leverage, 95% cash conversion. Worst-case bear scenario (cycle compression) floored by tangible asset value + dividend support. Hard floor for asymmetry case.

article

SWOT analysis

Strengths

+22-year unbroken dividend track record; conservative balance sheet
+Three diversified end-markets reduce single-customer concentration
+High gross margin (~50%); strong aftermarket revenue mix
+Long qualification cycles in A&I = sticky customer relationships
+Net cash position; zero leverage; ROCE ~16%

Weaknesses

−Sub-scale vs UK quality industrial peers (HLMA, DPLM, SXS)
−Metal Melt Quality drags blended margin and multiple
−Low liquidity / institutional ownership constrains rerating speed
−No M&A platform; organic-only growth profile
−Board cohesion question after 24% AGM no-confidence

Opportunities

→Aerospace OEM build-rate ramp into 2027 lifts A&I demand
→Lab destock cycle ending; biopharma capex normalisation
→Activist-led strategic review could unlock 30-50% takeover premium
→Buyback capacity (10% AGM authority + net cash) untapped
→SotP exceeds current EV — potential divest of MMQ at multiple

Threats

!Aerospace cycle peak; Boeing/Airbus production cuts
!Sustained GBP strength erodes reported revenue
!Activist campaign fizzles → value-trap risk at 9-10x EV/EBITDA
!Lab destock extends into FY27, delaying margin recovery
!Larger consolidator pre-empts the activist process at low premium

article

Summary by assessment area

🟢 Financial Risk — LOW

Net cash £8.4M; zero leverage
95% cash conversion; ROCE ~16%
22-yr dividend record; 5.8x cover
Resilient to 1-2 year cyclical downturn

🟡 Catalyst Execution — MEDIUM

H1 26 interim 29 Jun 2026 = near-term test
Activist non-binding; outcome 6-12 months
No formal sale process announced yet
Board response to AGM vote pending

🟢 Valuation & R/R — FAVORABLE

~30% EV/EBITDA discount to peer median
Asymmetry ratio 5.4x (bull/|bear|)
Hard floor from cash + quality of business
FV 960p (+18.5% base) / 1,250p (+54% bull)

Sources & Disclaimer

Sources: Yahoo Finance (PRV.L), MarketBeat, Stockopedia, Simply Wall St, Sharecast, Investegate (RNS announcements), StockInvest.us, TradingView, London Stock Exchange. Market data — last verified close 2026-05-28 at 860p; working "current price" reference 810p sourced from analyst-consensus calculation context (Stockopedia, MarketBeat) in mid-Jun 2026 but exact date not confirmable to T-1 (2026-06-19); STALE PRICE WARNING applied. PRV ~810p, market cap ~£377M, 52W: 660-920p, 46.5M shares outstanding. Short interest: <1% (below UK disclosure threshold). EBITDA TTM £32.8M; net cash £8.4M; dividend yield ~0.83%. Activist context: Richard Bernstein public push for strategic alternatives on 2026-05-19; AGM 2026 saw 24% vote against chairman re-election. This document is for informational purposes only and does not constitute financial or investment advice.